Dr. Vogelzang on Cabozantinib Clinical Trial Results

Nicholas J. Vogelzang, MD
Published: Monday, Jun 20, 2011

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses the cabozantinib clinical trial results.

Dr. Vogelzang says hepatocellular, melanoma, lung and breast cancer patients had minorities of patients, somewhere between 20% and 40% of patients in the trial. In the subset of hepatocellular, over 50% of patients had clinical benefit, namely either tumor shrinkage, dropping of blood tests, reduced pain, etc. The groups that didn't seem to benefit were the gastrointestinal tumor population and the small cell lung cancer population. The ovarian cancer and prostate cancer groups were so obviously benefitting that they were reported as individual reports.
Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses the cabozantinib clinical trial results.

Dr. Vogelzang says hepatocellular, melanoma, lung and breast cancer patients had minorities of patients, somewhere between 20% and 40% of patients in the trial. In the subset of hepatocellular, over 50% of patients had clinical benefit, namely either tumor shrinkage, dropping of blood tests, reduced pain, etc. The groups that didn't seem to benefit were the gastrointestinal tumor population and the small cell lung cancer population. The ovarian cancer and prostate cancer groups were so obviously benefitting that they were reported as individual reports.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x